VXRT - vaxart.com Operating income before deduction of amortization

Graphic logo of Vaxart Inc. (VXRT)

Vaxart, Inc. (VXRT) is developing innovative tablet-based vaccines for influenza and norovirus, leveraging support from BARDA and Phase 2 results. Monitoring EBITDA_Co allows for the tracking of actual cash flow, where serves as the final level marker. The business's success is based on patent protection and the confirmation of an immune response. The company is currently in the clinical testing stage, operating on grants.

VXRT - Vaxart Inc. Operating profit before deduction of amortization over the range 07/04/2022 - 11/12/2026

Vaxart - analytical breakdowns and key metrics (VXRT)

- stock price and consensus target price:
Price Chart Vaxart Inc.|VXRT - Analyst Consensus Forecast
- market capitalization statistics:
Market Capitalization Vaxart|VXRT - Total Company Value
- balance sheet equity data:
Accounting Value of a Share Vaxart|VXRT - Company Net Assets|Market Capitalization to Book Value Ratio vaxart.com|VXRT - Aggregate Company Assets
- debt level and financial liquidity data:
Total Debt to Capital Coefficient Vaxart, Inc.|VXRT - Long-Term Debt to Equity Ratio|Short-Term Debt to Equity Vaxart Inc.|VXRT - Company Aggregate Debts|Debts to Book Capitalization Vaxart|VXRT - Company Long-Term Liabilities|Company Short-Term Indebtedness Vaxart|Quick Ratio vaxart.com
- earnings and market ratios statistics:
VXRT - Company Net Income|Expected Net Income Vaxart, Inc.|VXRT - Price to Earnings Ratio|Market Cap to Future Earnings Ratio Vaxart Inc.|VXRT - Price/Earnings to Growth Multiple|Business Value to Operating Income Before Depreciation Vaxart|VXRT - Operating profit EBITDA|Net earnings per share for the last four quarters Vaxart|VXRT - Earnings per share for the last twelve months|Year-over-year earnings per share growth for the last 12 months vaxart.com|VXRT - Earnings growth in current year|Expected earnings per share growth for next year Vaxart, Inc.
Summary company analytics:VXRT (Vaxart, Inc.)
Signature product of Vaxart Inc.

Absolute operating profit measures cash flow from core operations before depreciation and amortization, reflecting the business's ability to generate internal resources during periods of market volatility. This chart of operating profit before depreciation and amortization allows for an assessment of the financial model's resilience at Vaxart, Inc. (VXRT) amid the costly scaling of its oral vaccine platform and its dependence on government funding for clinical trials.

Competitor analysis for Vaxart, Inc.

Gilead Corp - Profit before payment of interest, taxes and amortization|Cidara Therapeutics, Inc. - Operating profit EBITDA|Operating income before deduction of amortization novavax.com NVAX|CureVac (CVAC) - Profit before payment of interest, taxes and amortization|Valneva Corp - Income before deduction of interest, taxes and amortization|Operating profit before deduction of amortization VIR|Operating profit EBITDA TPOXX|Profit before payment of interest, taxes and amortization Emergent BioSolutions (EBS)|Operating income before deduction of amortization ateapharma.com|Invivyd - Operating profit before deduction of amortization|Enanta Pharmaceuticals Inc. - Profit before payment of interest, taxes and amortization|Inovio Pharmaceuticals Inc - Operating profit EBITDA|HLVX - Operating profit EBITDA|KLRS (Kalaris Therapeutics Inc) - Operating profit before deduction of amortization|Operating profit before amortization DYAI|NNVC (NanoViricides Inc.) - Operating profit EBITDA|Operating profit EBITDA Talphera Inc|Profit before payment of interest, taxes and amortization Cocrystal (COCP)|TRAW (trawspharma.com) - Income before deduction of interest, taxes and amortization|Dogwood Therapeutics - Operating profit before deduction of amortization|Company profit before taxes, interest and amortization QLGN (qualigeninc.com)|ALVR: Operating profit before deduction of amortization|Income before deduction of interest, taxes and amortization VBIV (VBI Vaccines Inc.)|VIRI: Operating profit EBITDA